AI-Powered Translational Research
Revalia Bio delivers organ-based human data to bridge the gap between bench research and clinical success — powered by AI and validated by science.
Average cost to bring a single drug to market
Clinical trial failure rate
Average time from discovery to approval
ARPA-H contract award — validating our approach
Trusted By
Founded in 2023 by Yale scientists, Revalia Bio was created to address a structural gap in drug and device development: the absence of scalable human-relevant data.
Biomedical research and therapeutic development are entering a new era—one centered around human data. The challenge is that scalable access to human tissue and biological data remains limited.
Revalia is helping enable this shift through its integrated human data stack, a system designed to generate human biological data at scale.
The human data stack captures patient-level context from revived, donated human organs. It integrates multiple data sources–patient samples, human organs, biopsy & tissue slices, and organoids and organ-on-a-chip models–to generate high-fidelity biological insights.
The system powers structured organ-level studies that generate human biological data, helping answer critical translational questions about:
By providing organ-level human insight, Revalia helps researchers reduce translational uncertainty and strengthen decision-making across the drug and device development process.
Learn more about how Revalia generates human biological data.Revalia strengthens development confidence by:
Trusted by two of the world's top 10 pharmaceutical companies.
Through partnerships with organ procurement organizations and academic healthcare systems, our team can bring a non-transplantable organ back to life on a perfusion system.
We turn the gift of organ donation into a powerful engine for discovery. Each donation provides researchers with governed access to regulatory-grade human data and gives purpose to the donor's legacy.
Revalia's studies have enabled insights such as understanding chronic kidney disease, performing an image-guided drug-delivery study on a perfused liver, or making a lung breathe again using clinical-grade imaging.
Read more use cases.Five integrated layers powering the world's first Human Data Trials infrastructure.
Nationwide delivery of viable human organs from trusted sources. Rapid access to diverse patient profiles. The foundation of every Human Data Trial.
Proprietary organ perfusion technology. 8,000 sq ft facility in New Haven, CT. 24/7 support from transplant surgeons. Organs kept viable for research using cutting-edge perfusion systems.
Four layers of human biological data — patient history, organ function, tissue biopsies, and organoid data — integrated and accessible through our software.
Rio Assist for data input and management. Rio Insight for designing and running Human Data Trials. Purpose-built for translational research.
Expert guidance on trial design, regulatory support, and industry collaboration. Connecting pharma, biotech, and researchers with the right expertise.
I've been chasing this type of opportunity for ~8 years. The challenge has been the infrastructure to facilitate research donor organs paired with having the folks skilled to perform the experiments on short notice. The team at Revalia has addressed these challenges and have opened the door for some incredible research opportunities.
— Revalia Customer, Top 10 Pharma Company
From question to decision-grade data in three steps
Define the development question and align endpoints with your program goals.
Conduct organ-level studies with clinical precision using our perfusion infrastructure.
Receive integrated, multi-modal human data to advance or refine your pipeline.
Ready to accelerate your next program? Schedule a meeting with our team to explore how Human Data Trials can transform your pipeline.